UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Chronic renal allograft nephropathy

Authors
John Vella, MD, FACP, FRCP, FASN
Daniel C Brennan, MD, FACP
Section Editor
Barbara Murphy, MB, BAO, BCh, FRCPI
Deputy Editor
Albert Q Lam, MD

INTRODUCTION

Renal allograft failure is one of the most common causes of end-stage renal disease (ESRD), accounting for 25 to 30 percent of patients awaiting renal transplantation. Similarly, over 20 percent of kidney transplants performed in the United States go to patients who have failed one or more renal allografts.

The most common cause of graft failure after the first year is an incompletely understood clinicopathological entity variously called chronic rejection, transplant nephropathy, chronic renal allograft dysfunction, transplant glomerulopathy (TG), chronic allograft injury, or chronic renal allograft nephropathy [1-10].

The revised Banff 2005 classification system, which was reported in 2007, renamed chronic allograft nephropathy, "interstitial fibrosis and tubular atrophy (IF/TA), without evidence of any specific etiology" [11]. This was done because the term "chronic allograft nephropathy" was thought to diminish attempts to determine the underlying cause of the histologic lesions.

The Banff 2005 classification also added the category "chronic active antibody-mediated rejection (AMR)" as a subset of AMR. It is characterized by C4d+, presence of circulating anti-donor antibodies, and morphologic evidence of chronic tissue injury, such as glomerular double contours and/or peritubular capillary basement membrane multilayering and/or IF/TA and/or fibrous intimal thickening in arteries.

In the Banff 2013 classification, the requirement for C4d staining for the diagnosis of acute/active and chronic active AMR was replaced by histologic evidence of antibody interaction with the endothelium [12]. Such evidence could include positivity, moderate microvascular inflammation, or increased gene expression suggestive of endothelial injury. Importantly, the Banff group recognized the existence of C4d-negative AMR.

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Sep 06 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46:266.
  2. Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl 1995; 50:S40.
  3. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10:167.
  4. Monaco AP, Burke JF Jr, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33:150.
  5. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56:783.
  6. Suri DL, Tomlanovich SJ, Olson JL, Meyer TW. Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000; 35:674.
  7. Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68:1.
  8. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16:3015.
  9. Afzali B, Taylor AL, Goldsmith DJ. What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int 2005; 68:2429.
  10. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8:492.
  11. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.
  12. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272.
  13. Yakupoglu U, Baranowska-Daca E, Rosen D, et al. Post-transplant nephrotic syndrome: A comprehensive clinicopathologic study. Kidney Int 2004; 65:2360.
  14. Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.
  15. Gouldesbrough DR, Axelsen RA. Arterial endothelialitis in chronic renal allograft rejection: a histopathological and immunocytochemical study. Nephrol Dial Transplant 1994; 9:35.
  16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.
  17. Wang Y, Pratt JR, Hartley B, et al. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997; 52:371.
  18. Gough J, Yilmaz A, Miskulin D, et al. Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens. Transplantation 2001; 71:1390.
  19. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464.
  20. Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17:881.
  21. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753.
  22. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312.
  23. Serón D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51:310.
  24. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9:482.
  25. Serón D, Moreso F, Ramón JM, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69:1849.
  26. Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2014; 19:315.
  27. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428.
  28. Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32:582.
  29. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.
  30. Noris M, Mister M, Pezzotta A, et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64:2253.
  31. Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation 2003; 75:1677.
  32. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67:341.
  33. Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27:151.
  34. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101:2309.
  35. Orth SR, Odoni G, Amann K, et al. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol 1999; 10:387.
  36. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69:1759.
  37. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345:93.
  38. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72:77.
  39. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13:519.
  40. Mróz A, Durlik M, Cieciura T, et al. C4d complement split product expression in chronic rejection of renal allograft. Transplant Proc 2003; 35:2190.
  41. Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65:2409.
  42. Akalin E, Dikman S, Murphy B, et al. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003; 3:1116.
  43. Koh KP, Wang Y, Yi T, et al. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest 2004; 114:846.
  44. Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5:383.
  45. Melenhorst WB, van den Heuvel MC, Stegeman CA, et al. Upregulation of ADAM19 in chronic allograft nephropathy. Am J Transplant 2006; 6:1673.
  46. Herrero-Fresneda I, Torras J, Franquesa M, et al. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006; 70:265.
  47. Terasaki PI, Cecka JM, Cho Y. Overview. In: Clinical Transplants, Terasaki PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1989. p.585.
  48. Opelz G, Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365:1570.
  49. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752.
  50. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.
  51. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857.
  52. Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68:1200.
  53. Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69:2357.
  54. Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56:307.
  55. Arias M, Serón D, Moreso F, et al. Chronic renal allograft damage: existing challenges. Transplantation 2011; 91:S4.
  56. Keith DS, DeMattos A, Golconda M, et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16:1512.
  57. Bia MJ. Nonimmunologic causes of late renal graft loss. Kidney Int 1995; 47:1470.
  58. Melk A, Gourishankar S, Halloran PF. Long-term effects of nonimmune tissue injury in renal transplantation. Curr Opin Organ Transplant 2002; 7:171.
  59. Bhathena DB. Glomerular size and the association of focal glomerulosclerosis in long-surviving human renal allografts. J Am Soc Nephrol 1993; 4:1316.
  60. Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3:162.
  61. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57:1450.
  62. Mackenzie HS, Tullius SG, Heemann UW, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994; 94:2148.
  63. Miles AM, Sumrani N, John S, et al. The effect of kidney size on cadaveric renal allograft outcome. Transplantation 1996; 61:894.
  64. Gaston RS, Hudson SL, Julian BA, et al. Impact of donor/recipient size matching on outcomes in renal transplantation. Transplantation 1996; 61:383.
  65. Diaz Encarnacion MM, Griffin MD, Slezak JM, et al. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2004; 4:248.
  66. Pape L, Henne T, Offner G, et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76:955.
  67. Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8:101.
  68. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int Suppl 1995; 52:S56.
  69. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675.
  70. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326.
  71. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81:643.
  72. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11:698.
  73. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580.
  74. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:860.
  75. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:1706.
  76. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59:1567.
  77. Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77:215.
  78. Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64:1027.
  79. François H, Dürrbach A, Amor M, et al. The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 2003; 18:1909.
  80. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4:655.
  81. Montagnino G, Banfi G, Campise MR, et al. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation. Nephrol Dial Transplant 2004; 19:2622.
  82. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75:772.
  83. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78:1653.
  84. Cantarovich D, Renou M, Megnigbeto A, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005; 79:72.
  85. Afzali B, Shah S, Chowdhury P, et al. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79:304.
  86. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74:1725.
  87. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16:2234.
  88. Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16:2509.
  89. Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81:1035.
  90. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755.
  91. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5:1748.
  92. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777.
  93. Ruiz JC, Campistol JM, Grinyó JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78:1312.
  94. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15:809.
  95. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4:953.
  96. Russ G, Segoloni G, Oberbauer R, et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80:1204.
  97. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6:2725.
  98. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153.
  99. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7:1572.
  100. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535.
  101. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547.
  102. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770.
  103. Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22:2107.
  104. Sawinski D, Trofe-Clark J, Leas B, et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant 2016; 16:2117.
  105. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514.
  106. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77:244.
  107. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77:252.
  108. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81:845.
  109. Moreso F, Serón D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78:1064.
  110. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776.
  111. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83:883.
  112. Jevnikar A, Arlen D, Barrett B, et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation 2008; 86:953.
  113. Merville P, Bergé F, Deminière C, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4:1769.
  114. Halloran PF, Langone AJ, Helderman JH, Kaplan B. Assessing long-term nephron loss: is it time to kick the CAN grading system? Am J Transplant 2004; 4:1729.
  115. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79:466.
  116. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24:379.
  117. Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87:591.
  118. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.
  119. Hricik DE, Formica RN, Nickerson P, et al. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. J Am Soc Nephrol 2015; 26:3114.
  120. http://www.clinicaltrials.gov/ct2/show/NCT00307125?term=ctot-02&rank=1 (Accessed on May 14, 2010).
  121. Grotz W, Siebig S, Olschewski M, et al. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004; 77:1848.
  122. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.
  123. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257.
  124. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.
  125. Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24:320.
  126. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73:783.
  127. Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19:940.
  128. Artz MA, Hilbrands LB, Borm G, et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19:2852.
  129. O'Herrin JK, Hullett DA, Heisey DM, et al. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002; 22:515.
  130. Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22:321.
  131. O'Connell PJ, Zhang W, Menon MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 2016; 388:983.